AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27169834 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin-propionate ester
Number of subjects: 20
Study 27169834 — intervention group
Group type: COMPARATOR
Intervention: Control inulin
Number of subjects: 20
Study 24925094 — intervention group
Group type: EXPERIMENTAL
Intervention: True needle acupuncture for ten treatments over eight weeks
Number of subjects: 360
Study 24925094 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture with non‐insertive (blunt) needles for ten treatments over eight weeks
Number of subjects: 360
Study 23101480 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab in addition to standard treatment with steroid-boli
Number of subjects: 180
Study 23101480 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (placebo)
Number of subjects: 180
Study 19701637 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab, administered in a clinical setting, dosage not specified, duration of treatment not specified.
Number of subjects: 61
Study 17681004 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon Advance (10 ml)
Number of subjects: 0
Study 17681004 — intervention group
Group type: EXPERIMENTAL
Intervention: New tablet product containing the same active ingredients as Gaviscon Advance
Number of subjects: 0
Study 17681004 — intervention group
Group type: COMPARATOR
Intervention: Control (10 ml water)
Number of subjects: 0
Study 15452671 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors and/or beta-blockers
Number of subjects: 167
Study 15452671 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional treatment)
Number of subjects: 167
Study 12103458 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 12103458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9682114 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-surface-modified (HSM) convex-plano laser-ridge IOL
Number of subjects: 246
Study 9682114 — intervention group
Group type: COMPARATOR
Intervention: Conventional unmodified convex-plano lens
Number of subjects: 246
Study 7598916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 60
Study 7598916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7598916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 2113492 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate and human menopausal gonadotropin (hMG); 55 cycles
Number of subjects: 76
Study 2113492 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a) and hMG; 38 cycles
Number of subjects: 76
Study 360842 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 1 per cent vaginal cream for 7 days
Number of subjects: 65
Study 360842 — intervention group
Group type: COMPARATOR
Intervention: Miconazole nitrate 2 per cent vaginal cream for 14 days
Number of subjects: 65
Study 31392862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic Injury with major visceral Vascular Injury (PIVI group)
Number of subjects: 68
Study 31392862 — intervention group
Group type: COMPARATOR
Intervention: Pancreatic Injury without vascular injury (PI group)
Number of subjects: 68
Study 31392862 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVI group
Number of subjects: 68
Study 31392862 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVI group (AAST grade 1 and 2)
Number of subjects: 68
Study 31392862 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVI group (AAST grade 3, 4 and 5)
Number of subjects: 68
Study 29178758 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg(OH)2 dentifrice
Number of subjects: 18
Study 29178758 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF (1,450 ppm F) dentifrice
Number of subjects: 18
Study 29178758 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride (control) dentifrice
Number of subjects: 18
Study 26347460 — intervention group
Group type: EXPERIMENTAL
Intervention: One-site phacotrabeculectomy
Number of subjects: 34
Study 26347460 — intervention group
Group type: COMPARATOR
Intervention: Two-site phacotrabeculectomy
Number of subjects: 34
Study 23351825 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 2061
Study 23351825 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SBP
Number of subjects: 2061
Study 23351825 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge/day 7 SBP
Number of subjects: 2061
Study 23351825 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital SBP change
Number of subjects: 2061
Study 21296317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilotax stent
Number of subjects: 111
Study 21296317 — intervention group
Group type: COMPARATOR
Intervention: Taxus Liberte stent
Number of subjects: 111
Study 19321945 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 401
Study 19321945 — intervention group
Group type: COMPARATOR
Intervention: Sodium ozagrel
Number of subjects: 401
Study 17296460 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril (up to 20 mg/d)
Number of subjects: 122
Study 17296460 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (up to 16 mg/d)
Number of subjects: 122
Study 12575976 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (five-month training program)
Number of subjects: 20
Study 12575976 — intervention group
Group type: COMPARATOR
Intervention: Non-trained control group
Number of subjects: 20
Study 10526524 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 12
Study 8544215 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral suspension of antibiotic-resistant Bifidobacterium longum for 30 days, commencing 10-12 days post-irradiation.
Number of subjects: 5
Study 8544215 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control group).
Number of subjects: 5
Study 1830860 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (oral)
Number of subjects: 22
Study 1830860 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 22
Study 6228933 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine treatment
Number of subjects: 0
Study 6228933 — intervention group
Group type: COMPARATOR
Intervention: Alzheimer's patients
Number of subjects: 0
Study 6228933 — intervention group
Group type: COMPARATOR
Intervention: Young normals (ages 18-32)
Number of subjects: 0
Study 6228933 — intervention group
Group type: COMPARATOR
Intervention: Older group (ages 55-69)
Number of subjects: 0
Study 6228933 — intervention group
Group type: COMPARATOR
Intervention: Elderly group (ages 70-85)
Number of subjects: 0
Study 31056423 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medical group visits intervention
Number of subjects: 338
Study 26933839 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention (attending five sessions)
Number of subjects: 0
Study 26933839 — intervention group
Group type: EXPERIMENTAL
Intervention: Client engagement rating
Number of subjects: 0
Study 23824632 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-number comparison
Number of subjects: 0
Study 23824632 — intervention group
Group type: COMPARATOR
Intervention: Large-number comparison
Number of subjects: 0
Study 22248500 — intervention group
Group type: EXPERIMENTAL
Intervention: sprint interval exercise
Number of subjects: 10
Study 19070995 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (100-400mg/day)
Number of subjects: 38
Study 19070995 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (1-4mg/day)
Number of subjects: 38
Study 17311981 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (specific strains not detailed)
Number of subjects: 0
Study 17311981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15213636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gacyclidine 0.02 mg/kg
Number of subjects: 51
Study 15213636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gacyclidine 0.005 mg/kg
Number of subjects: 51
Study 15213636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gacyclidine 0.001 mg/kg
Number of subjects: 51
Study 15213636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11739092 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 0
Study 10441239 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 31
Study 10441239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 10441239 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 31
Study 7796359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium dissolved in normal saline
Number of subjects: 80
Study 7796359 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium dissolved in solvent
Number of subjects: 80
Study 2664089 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (mean dose 444 mg daily)
Number of subjects: 28
Study 2664089 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (mean dose 50 mg daily)
Number of subjects: 28
Study 918999 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy prior to radiotherapy
Number of subjects: 0
Study 918999 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with a focal dose of 3000 rd within three weeks
Number of subjects: 0
Study 918999 — intervention group
Group type: EXPERIMENTAL
Intervention: Different chemotherapeutic combinations
Number of subjects: 0
Study 31292709 — intervention group
Group type: EXPERIMENTAL
Intervention: BCD-055
Number of subjects: 426
Study 31292709 — intervention group
Group type: COMPARATOR
Intervention: IFX (innovator infliximab)
Number of subjects: 426
Study 29156619 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-dense and protein-rich early enteral nutrition (1300 Kcal/L and 66.7 g/L protein)
Number of subjects: 40
Study 29156619 — intervention group
Group type: COMPARATOR
Intervention: Standard isocaloric early enteral nutrition (1000 Kcal/L and 38 g/L protein)
Number of subjects: 40
Study 25907158 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone (300 mg three times a day)
Number of subjects: 64
Study 25907158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 23587747 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-computer interaction-based comprehensive cognitive training for 24 weeks
Number of subjects: 33
Study 23587747 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study 20833659 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopic surveillance in familial colorectal cancer
Number of subjects: 551
Study 19242030 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepid sponging and antipyretic drug (Paracetamol) (n=73)
Number of subjects: 150
Study 19242030 — intervention group
Group type: COMPARATOR
Intervention: Only antipyretic drug (Paracetamol) (n=77)
Number of subjects: 150
Study 17854249 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of depression symptoms
Number of subjects: 441
Study 17854249 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of mania/hypomania symptoms
Number of subjects: 441
Study 17854249 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in depression
Number of subjects: 441
Study 17854249 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in mania/hypomania
Number of subjects: 441
Study 15082581 — intervention group
Group type: EXPERIMENTAL
Intervention: GFD with additional wheat free oat products (GFD-oats)
Number of subjects: 116
Study 15082581 — intervention group
Group type: COMPARATOR
Intervention: Standard gluten free diet (GFD-std)
Number of subjects: 116
Study 11717609 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic study of the eustachian valve in patients suspected of endocarditis
Number of subjects: 152
Study 11717609 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-guided antibiotics for treatment
Number of subjects: 152
Study 11717609 — intervention group
Group type: COMPARATOR
Intervention: Blinded evaluation of eustachian valve findings
Number of subjects: 152
Study 9204354 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopentol (Imagopaque 300 mg I/ml)
Number of subjects: 97
Study 9204354 — intervention group
Group type: COMPARATOR
Intervention: Iopromide (Ultravist 300 mg I/ml)
Number of subjects: 97
Study 7950109 — intervention group
Group type: EXPERIMENTAL
Intervention: Frown incision (A)
Number of subjects: 95
Study 7950109 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal arc incision (B)
Number of subjects: 95
Study 7950109 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbus-based incision (C)
Number of subjects: 95
Study 7950109 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezoid incision with 2-mm tunnel
Number of subjects: 95
Study 7950109 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezoid incision with 4-mm tunnel
Number of subjects: 95
Study 2847843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA)
Number of subjects: 59
Study 2847843 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 59
Study 47081 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant feeding-bottle with a valve
Number of subjects: 0
Study 47081 — intervention group
Group type: COMPARATOR
Intervention: Conventional feeding-bottles
Number of subjects: 0
Study 47081 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard teat under valve conditions
Number of subjects: 0
Study 30839402 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine-A treatment for 8 weeks
Number of subjects: 50
Study 30839402 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 50
Study 29236711 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 61
Study 29236711 — intervention group
Group type: COMPARATOR
Intervention: DCE‐MRI and RAMRIS
Number of subjects: 61
Study 29236711 — intervention group
Group type: COMPARATOR
Intervention: RAMRIS and CARLOS
Number of subjects: 61
Study 26179113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (3 g/day) with low-calorie diet
Number of subjects: 50
Study 26179113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 g/day) with low-calorie diet
Number of subjects: 50
Study 23388213 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cardiac resynchronization therapy
Number of subjects: 85
Study 23388213 — intervention group
Group type: COMPARATOR
Intervention: Inactive cardiac resynchronization therapy
Number of subjects: 85
Study 21973230 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0
Study 21973230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19339233 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg meloxicam (formulation 1)
Number of subjects: 12
Study 19339233 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg meloxicam (formulation 2)
Number of subjects: 12
Study 19339233 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 12
Study 22795204 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-089 40 mg once daily
Number of subjects: 160
Study 22795204 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-089 80 mg once daily
Number of subjects: 160
Study 22795204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 15993398 — intervention group
Group type: EXPERIMENTAL
Intervention: Actor grasping the object inside the short frame
Number of subjects: 100
Study 15993398 — intervention group
Group type: COMPARATOR
Intervention: Actor grasping the object inside the long frame
Number of subjects: 100
Study 12447010 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine EC (400 mg once daily), Stavudine (40 mg twice daily), Nelfinavir (750 mg three times daily)
Number of subjects: 511
Study 12447010 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (300 mg twice daily) plus Lamivudine (150 mg twice daily) and Nelfinavir (750 mg three times daily)
Number of subjects: 511
Study 9804035 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovered depressed subjects
Number of subjects: 0
Study 9804035 — intervention group
Group type: COMPARATOR
Intervention: Matched control groups
Number of subjects: 0
Study 7638372 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 50 micrograms twice daily
Number of subjects: 225
Study 7638372 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) 20 mg four times daily
Number of subjects: 225
Study 7638372 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 225
Study 7638372 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 225
Study 2797637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (50-100 micrograms every hour)
Number of subjects: 105
Study 2797637 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (25-50 mg every 2-3 hours)
Number of subjects: 105
Study 2797637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 105
Study 2797637 — intervention group
Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 105
Study 2797637 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 105
Study 355954 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 0
Study 355954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 355954 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 11673575 — intervention group
Group type: COMPARATOR
Intervention: rizatriptan 10 mg
Number of subjects: 4064
Study 31499564 — intervention group
Group type: EXPERIMENTAL
Intervention: Light load (LIT) - 25-30 repetitions maximum (RM)
Number of subjects: 12
Study 31499564 — intervention group
Group type: COMPARATOR
Intervention: Moderate load (MOD) - 8-12 repetitions maximum (RM)
Number of subjects: 12
Study 30253264 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a‐tDCS)
Number of subjects: 36
Study 30253264 — intervention group
Group type: COMPARATOR
Intervention: Sham/placebo stimulation
Number of subjects: 36
Study 28139613 — intervention group
Group type: EXPERIMENTAL
Intervention: BCD-063 (glatiramer acetate)
Number of subjects: 158
Study 28139613 — intervention group
Group type: EXPERIMENTAL
Intervention: Copaxone-Teva (glatiramer acetate)
Number of subjects: 158
Study 28139613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 23983082 — intervention group
Group type: EXPERIMENTAL
Intervention: NURTURE intervention (weekly for 16 sessions, 1.5 hours each)
Number of subjects: 13
Study 23983082 — intervention group
Group type: EXPERIMENTAL
Intervention: NURTURE intervention
Number of subjects: 13
Study 22380529 — intervention group
Group type: EXPERIMENTAL
Intervention: LAR 30 mg
Number of subjects: 39
Study 22380529 — intervention group
Group type: EXPERIMENTAL
Intervention: LAR 10 mg
Number of subjects: 39
Study 22380529 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 39
Study 22380529 — intervention group
Group type: EXPERIMENTAL
Intervention: LAR 30 mg, LAR 10 mg, Saline (Control)
Number of subjects: 39
Study 20007995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke external support placement
Number of subjects: 10
Study 20007995 — intervention group
Group type: COMPARATOR
Intervention: Control group (unoperated Marfan patients)
Number of subjects: 10
Study 18377782 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid supplementation
Number of subjects: 0
Study 18377782 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish consumption (oily fish such as salmon)
Number of subjects: 0
Study 18377782 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced tissue/blood levels of LC n-3 FAs
Number of subjects: 0
Study 18377782 — intervention group
Group type: EXPERIMENTAL
Intervention: LC n-3 FA supplementation in cardiac surgery patients
Number of subjects: 0
Study 15023167 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenatoprazole 40 mg (T40)
Number of subjects: 18
Study 15023167 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenatoprazole 20 mg (T20)
Number of subjects: 18
Study 15023167 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg (E40)
Number of subjects: 18
Study 11792778 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-vacuum technique
Number of subjects: 130
Study 11792778 — intervention group
Group type: COMPARATOR
Intervention: Standard cementing technique (Control)
Number of subjects: 130
Study 9583368 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented TPN (0.22 g glutamine x kg(‐1) x d(‐1) as glycyl‐glutamine)
Number of subjects: 14
Study 9583368 — intervention group
Group type: COMPARATOR
Intervention: Conventional TPN
Number of subjects: 14
Study 9583368 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented TPN
Number of subjects: 14
Study 7658051 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 150
Study 7658051 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 150
Study 2651861 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 0
Study 2651861 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0
Study 2651861 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study 345709 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen film implantation
Number of subjects: 50
Study 30398542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive patient education (2 x 1-hour sessions providing information on pain and biopsychosocial contributors plus self-management techniques)
Number of subjects: 202
Study 30398542 — intervention group
Group type: COMPARATOR
Intervention: Placebo patient education (active listening without information or advice)
Number of subjects: 202
Study 30398542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive patient education
Number of subjects: 202
Study 28548301 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure withdrawal
Number of subjects: 77
Study 25837215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PRAL group
Number of subjects: 547